A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol.
Immunotherapy
Oligometastases
RCC
Renal cell carcinoma
SABR
SBRT
Journal
Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
15
03
2020
revised:
27
09
2020
accepted:
01
01
2021
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body radiotherapy (SABR). Immunotherapy combinations have shown survival benefits, however, toxicity is higher than that for monotherapy and complete response rates remain less than 10%. The combination of effective local therapies in conjunction with immunotherapy may provide more durable control and pre-clinical models have suggested a synergistic immune-priming effect of SABR. and Methods: RAPPORT is a prospective, single arm, phase I/II study assessing the safety, efficacy and biological effects of single fraction SABR followed by pembrolizumab for oligometastatic ccRCC. The study will include 30 patients with histological confirmed ccRCC and 1-5 oligometastases, one or more of which must be suitable for SABR. Patients can have received prior systemic therapy but not prior immunotherapy. A single 20Gy of SABR is followed 5 days later by 8 cycles of 200 mg pembrolizumab, every 3 weeks. Adverse events are recorded using CTCAE V4.03 and tumour response evaluated by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1). Tumour tissue and peripheral blood samples will be collected pre-, during and post-treatment to assess longitudinal changes in immune subsets. The RAPPORT study will provide important safety and early efficacy data on the combination of SABR and pembrolizumab in oligometastatic ccRCC and will provide an insight into the underlying biological effects of combination therapy. clinicaltrials.gov ID NCT02855203.
Sections du résumé
BACKGROUND
BACKGROUND
The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body radiotherapy (SABR). Immunotherapy combinations have shown survival benefits, however, toxicity is higher than that for monotherapy and complete response rates remain less than 10%. The combination of effective local therapies in conjunction with immunotherapy may provide more durable control and pre-clinical models have suggested a synergistic immune-priming effect of SABR.
OBJECTIVES
OBJECTIVE
and Methods: RAPPORT is a prospective, single arm, phase I/II study assessing the safety, efficacy and biological effects of single fraction SABR followed by pembrolizumab for oligometastatic ccRCC. The study will include 30 patients with histological confirmed ccRCC and 1-5 oligometastases, one or more of which must be suitable for SABR. Patients can have received prior systemic therapy but not prior immunotherapy. A single 20Gy of SABR is followed 5 days later by 8 cycles of 200 mg pembrolizumab, every 3 weeks. Adverse events are recorded using CTCAE V4.03 and tumour response evaluated by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1). Tumour tissue and peripheral blood samples will be collected pre-, during and post-treatment to assess longitudinal changes in immune subsets.
OUTCOMES AND SIGNIFICANCE
UNASSIGNED
The RAPPORT study will provide important safety and early efficacy data on the combination of SABR and pembrolizumab in oligometastatic ccRCC and will provide an insight into the underlying biological effects of combination therapy.
TRIAL REGISTRATION
BACKGROUND
clinicaltrials.gov ID NCT02855203.
Identifiants
pubmed: 33490707
doi: 10.1016/j.conctc.2021.100703
pii: S2451-8654(21)00006-5
pmc: PMC7807247
doi:
Banques de données
ClinicalTrials.gov
['NCT02855203']
Types de publication
Journal Article
Langues
eng
Pagination
100703Informations de copyright
© 2021 Published by Elsevier Inc.
Références
Cancer. 2008 Jul 1;113(1):78-83
pubmed: 18491376
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Ann Thorac Surg. 2005 Mar;79(3):996-1003
pubmed: 15734422
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e597-605
pubmed: 22608954
BJU Int. 2017 Nov;120(5):623-630
pubmed: 28188682
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Clin Cancer Res. 2015 Aug 15;21(16):3727-39
pubmed: 25869387
Eur Urol Oncol. 2019 Sep;2(5):515-523
pubmed: 31302061
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Urol. 1986 Aug;136(2):376-9
pubmed: 3735498
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
JAMA. 1999 May 5;281(17):1628-31
pubmed: 10235157
Acta Oncol. 2015 Feb;54(2):148-57
pubmed: 25140860
Curr Opin Urol. 2015 Sep;25(5):390-4
pubmed: 26075569
Nat Rev Urol. 2017 Sep;14(9):549-563
pubmed: 28631740
Eur Urol. 2013 Apr;63(4):646-52
pubmed: 23041360
Cancer Immunol Res. 2015 Jun;3(6):610-9
pubmed: 25701325